The Federal Trade Commission on Thursday issued what amounted to a warning to pharmaceutical companies about the legality of a widespread patenting strategy that experts say has helped keep inhaler costs high for patients with asthma and lung problems.
In a policy statement unanimously endorsed by the agency’s commissioners, the F.T.C.
said it “intends to scrutinize” whether companies are illegally engaging in an unfair method of competition when they exploit a regulatory loophole that can delay rivals from entering the market.
The policy statement did not single out any particular products.
“This seems to be a real problem, and one that could really be contributing to unaffordable medicines and drug products,” Lina Khan, the F.T.C.
Persons:
“, ” Lina Khan
Organizations:
Federal Trade Commission